Jaime Vieser Biography and Net Worth

Director of ZIOPHARM Oncology


Jaime Vieser has over 30 years of investment management and banking experience, which includes his involvement in numerous successful corporate restructurings and providing both start-up capital and guidance for emerging technology and biotech companies.

Since 2017, Mr. Vieser has been the manager of a private investment firm, Brushwood LLC. Mr. Vieser has over three decades of experience investing across various asset classes and served for nearly a decade as Managing Partner and co-principal of Castle Hill Asset Management LLC (“Castle Hill”), a multi-billion dollar asset manager and hedge fund. Mr. Vieser has a deep understanding of Ziopharm’s assets, governance, and financials as he is a sizable and long-term shareholder of the Company. Prior to founding Castle Hill, for 10 years Mr. Vieser was responsible for the High Yield Sales and Trading Group in London at Deutsche Bank AG, a multinational investment bank and financial services company. Earlier in his career, Mr. Vieser worked as a banker in the Leveraged Finance division of Bankers Trust Company, a bank holding company that was acquired by Deutsche Bank AG in 1999. Mr. Vieser holds a Bachelor’s degree in Economics from the University of Michigan and a Master’s in Business Administration from the Cox School of Business at Southern Methodist University.

How do I contact Jaime Vieser?

The corporate mailing address for Mr. Vieser and other ZIOPHARM Oncology executives is ONE FIRST AVENUE PARRIS BUILDING 34, BOSTON MA, 02129. ZIOPHARM Oncology can also be reached via phone at (617) 259-1970 and via email at [email protected]. Learn More on Jaime Vieser's contact information.

Has Jaime Vieser been buying or selling shares of ZIOPHARM Oncology?

Jaime Vieser has not been actively trading shares of ZIOPHARM Oncology in the last ninety days. Most recently, on Wednesday, September 29th, Jaime Vieser bought 100,000 shares of ZIOPHARM Oncology stock. The stock was acquired at an average cost of $1.91 per share, with a total value of $191,000.00. Learn More on Jaime Vieser's trading history.

Who are ZIOPHARM Oncology's active insiders?

ZIOPHARM Oncology's insider roster includes Kevin Boyle, Sr. (CEO), Eleanor de Groot (EVP), Heidi Hagen (Director), and Jaime Vieser (Director). Learn More on ZIOPHARM Oncology's active insiders.

Jaime Vieser Insider Trading History at ZIOPHARM Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2021Buy100,000$1.91$191,000.00View SEC Filing Icon  
See Full Table

Jaime Vieser Buying and Selling Activity at ZIOPHARM Oncology

This chart shows Jaime Vieser's buying and selling at ZIOPHARM Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ZIOPHARM Oncology Company Overview

ZIOPHARM Oncology logo
ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $1.08
Low: $0.82
High: $1.39

2 Week Range

Now: N/A

Volume

2,127,500 shs

Average Volume

2,008,312 shs

Market Capitalization

$187.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.71